In This Issue/Research Watch/News in Brief/News From the Iaslc Tobacco Control Committee  by unknown
Copyright © 2015 by the International Association for the Study of Lung Cancer
967Journal of Thoracic Oncology ®  •  Volume 10, Number 7, July 2015
IN THIS ISSUE
•	 The IASLC Lung Cancer 
Staging Project: Proposals 
for the Revisions of the 
T Descriptors in the 
Forthcoming Eighth Edition 
of the TNM Classification 
for Lung Cancer
The IASLC Staging and Prognostic Factors Committee analyzed 
a new IASLC international database of 77,156 evaluable patients 
diagnosed with lung cancer from 1999 to 2010, and provided 
recommendations for revisions of the T descriptors in the 8th 
edition of the tumor, node and metastasis (TNM) classification of 
lung cancer. There were 70,967 patients with non-small cell lung 
cancer, and 33,115 with a clinical or pathological classification, 
known tumor size, sufficient T information and no metastases. 
The results demonstrated a 3-cm cutpoint to significantly 
•	 Association of PDCD1 and 
CTLA-4 Gene Expression 
with Clinicopathological 
Factors and Survival in 
Non–Small-Cell Lung 
Cancer: Results from 
a Large and Pooled 
Microarray Database
This study analyzed a lung cancer microarray database of 1715 
patients to determine the relationship between gene expression 
of CTLA-4 (encodes cytotoxic-lymphocyte antigen 4) and 
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differentiate T1 from T2. Each cm in tumors of 1 to 
5 cm differentiated them with significantly different 
prognosis. Tumors of >5-≤7cm had prognosis 
equivalent toT3, and those of >7cm to T4, those 
with bronchial involvement <2 cm from carina, 
and total atelectasis/pneumonitis to T2, and those 
with diaphragm involvement to T4. The descriptor 
mediastinal pleura invasion was hardly used. As a 
result, the authors proposed changes to subclassify 
T1 into T1a (≤1cm), T1b (>1-≤2cm) and T1c (>2-
≤3cm); to subclassify T2 into T2a (>3-≤4cm) and T2b 
(>4-≤5cm); to reclassify tumors >5-≤7cm as T3; to 
reclassify tumors >7cm as T4; to group main bronchus 
involvement as T2 independent of distance from carina; 
to group partial and total atelectasis/pneumonitis as T2; 
to reclassify diaphragm invasion as T4; and to delete 
mediastinal pleura invasion as a T descriptor. (p. 990)
PDCD1 (encodes programmed cell death 1) and 
clinicopathological factors and survival. Significantly 
elevated expression of PDCD1 and CTLA-4 were 
observed in squamous carcinoma versus adenocarcinoma, 
in current/former smokers versus nonsmokers, and 
in TNM stage II versus stage I. Multivariate analysis 
demonstrated significant association between higher 
CTLA-4 expression with worse overall survival (OS) 
(hazard ratio [HR]: 1.96), but not in the case of PDCD1 
expression (HR: 1.22). Prospective studies are required 
to confirm the findings and determine its potential role 
in guiding personalized immune checkpoint inhibition 
therapy for lung cancer patients. (p. 1020)
The authors reported the results of a retrospective study of surgical 
intervention in non-small cell lung cancer (NSCLC) with pleural 
carcinomatosis in Japan using the Japanese Lung Cancer Registry in 
2004. Pleural carcinomatosis was found in 2.9% of registered NSCLC 
•	 Surgical Intervention for 
Non–Small-Cell Lung 
Cancer Patients with 
Pleural Carcinomatosis: 
Results from the Japanese 
Lung Cancer Registry in 
2004
patients (329/11,420). Patients without other metastatic 
disease (n=313) had a median survival time of 34.0 months 
and 5-year survival rate of 29.3%. The 5-year survival rate 
for 256 (81.8%) patients undergone primary tumor resection 
was 33.1%, and for 152 (48.6%) patients undergone 
macroscopic complete resection was 37.1%. Independent 
predictors of survival were Eastern Cooperative Oncology 
Group performance status (p < 0.001), best stage nodal  
status (p = 0.002), and the presence or absence of gross 
residual tumor  (p = 0.013), according to multivariate 
analysis. The authors concluded that 2.9% of patients 
in the NSCLC registry had pleural carcinomatosis, and 
macroscopic complete resection was associated with 
improved survival in these patients. (p. 1076)
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•	 Hormone Use, 
Reproductive History, and 
Risk of Lung Cancer: The 
Women’s Health Initiative 
Studies
The joint analysis of data from the Women’s Health Initiative 
(WHI) clinical trial and observational study aimed to determine the 
relationship between estrogen and estrogen-related reproductive 
factors and lung cancer risk in 160,855 women underwent hormone 
therapy (HT). After a median follow-up of 14 years, the findings 
demonstrated a reduced risk for women exposed to estrogen plus 
progestin for < 5 years (hazard ratio [HR] = 0.84) 
for all lung cancers. Increasing age at menopause 
was associated with a trend towards decreased risk 
(p
trend
=0.04), and increasing number of live births was 
associated with a trend towards increasing number of 
live births (p
trend
=0.03). Age 20–29 at first live birth had 
a reduced risk of non-small cell lung cancer  
(HR = 0.84). Risks varied according to smoking history, 
years of HT use and previous bilateral oophorectomy. 
Taken together, this study, via indirect measures of 
estrogen exposure to lung tissue, has yet to prove a 
strong association of lung cancer risk and reproductive 
history or HT use. Further studies are required in 
assessing mechanism and estrogen receptor expression 
in the lung in association with risk factors. (p. 1004)
RESEARCH WATCH
•	 High Level of 
Chromosomal Instability in 
Circulating Tumor Cells of 
ROS1-Rearranged Non-
Small-Cell Lung Cancer
patients, and 7.5 per 3 ml in ROS1-negative patients. 
ROS1-rearranged CTCs showed significantly higher 
copy number at baseline versus paired tumor biopsies 
in 3 patients with partial response or stable disease 
(P<0.0001), significantly higher copy number in 2 
patients resistant to crizotinib treatment (P<0.02), as 
well as high DNA content and gain of chromosomes. 
Taken together, the findings suggested the value of 
CTCs in non-invasive and sensitive detection of ROS1-
rearranged NSCLC patients. High tumor heterogeneity 
and increased numerical chromosomal instability found in 
ROS1-rearranged CTCs could indicate potential resistant 
mechanism to ROS1 inhibitor in these patients.
Pailler E, Auger N, Lindsay CR, et al. High level of 
chromosomal instability in circulating tumor cells of 
ROS1-rearranged non-small-cell lung cancer. Annals of 
Oncology, doi:10.1093/annonc/mdv165 (2015).
This study aimed to achieve 2 objectives: to determine if 
circulating tumor cells (CTCs) could be used to detect c-ros 
oncogene 1 (ROS1) chromosomal rearrangement, and to assess 
tumor heterogeneity of CTCs and tumor biopsies in ROS1-
rearranged NSCLC patients. ROS1 gene alterations were 
analyzed in CTCs from 4 ROS1-rearanged patients treated with 
crizotinib, and 4 ROS1-negative patients. All 4 ROS1-rearraged 
patients previously confirmed by tumor biopsy showed ROS1 
rearrangement in their CTCs. Median number of ROS1-rearranged 
CTCs at baseline was 34.5 per 3 ml blood in ROS1-rearranged 
•	 Pretreatment FDG-PET 
Metrics in Stage III Non–
Small Cell Lung Cancer: 
ACRIN 6668/RTOG 0235
A secondary analysis of American College of Radiology Imaging 
Network (ACRIN) 6668/Radiation Therapy Oncology Group 
(RTOG) 0235 prospective trial was conducted to evaluate the 
association between higher pre-treatment metabolic tumor 
volume (MTV), measured by 18F-fluorodeoxyglucose positron 
emission tomography (FDG-PET), and clinical outcomes in 
patients with stage III non-small cell lung cancer (NSCLC) treated 
with concurrent platinum-based chemoradiotherapy (CRT). The 
overall survival (OS) analysis included 214 patients and the local 
regional control (LRC) analysis included 189 patients. Multivariate 
analysis incorporating clinical and imaging data demonstrated 
that pretreatment MTV was an independent predictor of worse 
OS (hazard ratio [HR] = 1.04 per 10 cm3 increase; P < 0.001). 
High MTV was also linked to higher risk of locoregional failure 
at baseline (HR = 1.16 per 10 cm3 increase; P < 0.001), and at 
6 months (HR = 1.05 per 10cm3 increase; P < 0.001) but not 
at 12 months or later. Overall, this study indicates that higher 
pretreatment MTV is predictive of clinical outcomes for the study 
population. Quantitative PET measures could help stratify this 
group of patients in clinical trials.
Ohri N, Duan F, Machtay M, et al. Pretreatment FDG-PET 
metrics in stage III non–small cell lung cancer: ACRIN 6668/RTOG 
0235. Journal of the National Cancer Institute 107, doi:10.1093/
jnci/djv004 (2015).
Image source: FDA
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•	 Impact of Specific 
Epidermal Growth 
Factor Receptor (EGFR) 
Mutations and Clinical 
Characteristics on 
Outcomes After Treatment 
With EGFR Tyrosine 
Kinase Inhibitors Versus 
Chemotherapy in EGFR-
Mutant Lung Cancer: A 
Meta-Analysis
This meta-analysis of 7 trials, comparing first-line EGFR tyrosine 
kinase inhibitors (TKIs) with chemotherapy, evaluated the association 
between different EGFR mutations and progression-free survival 
(PFS) in 1,649 patients with advanced EGFR-mutated non-small cell 
lung cancer (NSCLC). Compared with chemotherapy, significantly 
improved PFS was observed in overall population (hazard ratio 
[HR] = 0.37) and in all subgroups treated with EGFR TKIs. Patients 
with tumors harboring exon 19 deletions experienced 50% greater 
benefit versus those with exon 21 L858R substitution 
(HR = 0.50; P
interaction
 < 0.001). Greater benefits were also 
observed in never-smokers (by 36%; HR = 0.32) versus 
current or former smokers (HR = 0.50; P
interaction
 < 0.001), 
and in women (by 27%; HR = 0.33) versus men  
(HR = 0.45; P
interaction
 = 0.02). Taken together, EGFR TKIs 
significantly prolong PFS in all patients with EGFR-
mutated NSCLC compared with chemotherapy. More 
specifically, these benefits were greatest in patients with 
exon 19 deletions, who are women and never-smokers. 
The findings could help inform future trial design and 
interpretation, economic analyses and drug development 
for this patient population.
Lee CK, Wu YL, Ding PN, et al. Impact of specific 
epidermal growth factor receptor (EGFR) mutations and 
clinical characteristics on outcomes after treatment with 
EGFR tyrosine kinase inhibitors versus chemotherapy 
in EGFR-mutant lung cancer: a meta-analysis. J Clin 
Oncol, doi:10.1200/jco.2014.58.1736 (2015).
•	 Does a Recent Cancer 
Diagnosis Predict Smoking 
Cessation? An Analysis 
from a Large Prospective 
US Cohort
analysis (n=12,538) with a quit rate of 43.0% vs. 33.8%. 
Similar results were observed by cancer site and stage. 
The authors concluded that a cancer diagnosis, even 
for cancers not associated with smoking and with a 
good prognosis, could be linked to increased, sustained 
quitting following diagnosis. The findings support 
cancer diagnosis as a teachable moment in cessation 
promotion.
Westmaas JL, Newton CC, Stevens VL, Flanders 
WD, Gapstur SM, Jacobs EJ. Does a Recent Cancer 
Diagnosis Predict Smoking Cessation? An Analysis 
From a Large Prospective US Cohort. J Clin Oncol, 
doi:10.1200/jco.2014.58.3088 (2015).
The Cancer Prevention Study-II Nutrition Cohort compared 
smoking quit rates of smokers during 2- and 4-year intervals (1992 
to 2009) between those diagnosed with cancer and those without. 
Cancers likely to cause physical limitations or symptoms that could 
affect smoking were excluded from the analysis. Among the 12,182 
smokers in the 2-year analysis, those diagnosed with cancer (n=772) 
had a higher 2-year quit rate versus those not diagnosed with cancer 
(31.3% vs. 19.5%). A similar observation was found in the 4-year 
•	 The Relations between 
False Positive and Negative 
Screens and Smoking 
Cessation and Relapse 
in the National Lung 
Cancer Screening Trial: 
Implications for Public 
Health.
This study assessed changes in smoking in 18,840 
current and former smokers aged 55–74, randomized 
to receive 3 annual lung screenings (low-dose CT or 
single-view chest radiography) in the National Lung 
Screening Trial (NLST). The analysis included point 
and sustained (6-month) abstinence and motivation to 
quit among smokers; and relapse among smokers who 
quit during follow-up, recent quitters (quit < 6 months), 
and long-term former smokers (quit ≥ 6 months). The 
results of a 5-year follow-up demonstrated a 11.6%-
13.4% annual point prevalence quit rates. A quit 
attempt was reported in 48% of current smokers while 
relapse occurred in 7% of long-term former smokers. 
Subsequent increased point and sustained abstinence 
among smokers were associated with false positive 
screens (multivariable hazard ratio HR=1.23 and 1.28, 
respectively). Recent quitters with ≥1 false positive 
screen had lower possibility to relapse (HR=0.72). 
Relapse among long-term former smokers or baseline 
smokers who quit during follow-up were not associated 
with screening results. Overall, the data indicate an 
association of false-positive screens with increased 
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smoking cessation and reduced relapse in recent 
quitters, and no association of negative screens with 
greater relapse in long-term former smokers. Smoking 
cessation intervention could further enhance the impact 
and cost-effectiveness of lung screening.
Clark MA, Gorelick JJ, Sicks JD, et al. The relations 
between false positive and negative screens and smoking 
cessation and relapse in the National Lung Cancer 
Screening Trial: implications for public health. Nicotine 
& tobacco research: official journal of the Society for 
Research on Nicotine and Tobacco, doi:10.1093/ntr/
ntv037 (2015).
NEWS IN BRIEF
•	 Crizotinib Granted 
Breakthrough Therapy 
Designation for ROS1-
Positive Non–Small Cell 
Lung Cancer
patients with ROS1-positive non-small cell lung cancer. 
The designation was based on the findings from a global 
phase I study expansion cohort, which demonstrated 
that crizotinib exhibited significant antitumor efficacy 
in ROS1-positive advanced NSCLC patients, with a 
comparable safety profile to that in anaplastic lymphoma 
kinase (ALK)-positive advanced NSCLC. Crizotinib is 
being approved in the U.S. for the treatment of patients 
with ALK-positive metastatic NSCLC.
Image source: FDA
The U.S. Food and Drug Administration (FDA) has granted 
Breakthrough Therapy designation to crizotinib for treatment in 
•	 ELCC 2015: Determining 
the Prevalence of EGFR 
Mutations in Asian and 
Russian Patients with 
Advanced Non-Small-
Cell Lung Cancer of 
Adenocarcinoma and 
Non- Adenocarcinoma 
Histology: IGNITE Study 
(Abstract: 96O)
The large, multinational, diagnostic, non-comparative, 
interventional IGNITE study evaluated tissue/cytology and plasma 
in Asian (2291 and 1753, respectively) and Russian (924 and 941, 
respectively) patients with advanced non-small-cell lung cancer 
(aNSCLC) of adenocarcinoma (ADC) and non-ADC histology 
for EGFR mutation frequency. Tissue/cytology (Asian/Russian) 
showed a frequency of 49/18% in ADC and 14/4% in non-ADC 
while plasma had a lower overall frequency of 22% in ADC 
and 7% in non-ADC. Exon 19 deletion was the most frequently 
mutated (49/59% Asian/Russian), followed by L858R (42/25%), 
Exon 20 insertions (2/0%), L861Q and G879X (both 
≤1% overall). Mutation status concordance between 
tumor and plasma exhibited higher sensitivity (50 vs. 
30%) and positive predictive value (93 vs. 39%) in Asia 
versus Russia. EGFR mutation was found positive in 
50/47% (Asia/Russia) and negative in 38/43% (Asia/
Russia) NSCLC patients. Overall, the most common 
first-line treatment was gefitinib for EGFR-positive 
NSCLC (36%), and cisplatin for EGFR-negative 
NSCLC (41%). The overall population showed a 
significant association of ADC and never-smoker 
status with the mutation frequency in tissue/cytology 
and plasma (p<0.0001). The mutation frequency in 
both Asian and Russian cohorts (both p<0.0001) was 
significantly associated with more metastatic organs 
(plasma p<0.0001), female gender (tissue/cytology 
p<0.0075), and age ≥65 years (plasma p<0.0009). In 
summary, the “real world” EGFR mutation frequency 
in chemotherapy-naive aNSCLC patients is higher in 
ADC than non-ADC. The data support mutation testing 
for all patients.
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•	 ELCC 2015: Investigating 
the Utility of Circulating-
Free Tumor-Derived 
DNA in Plasma for the 
Detection of Epidermal 
Growth Factor Receptor 
Mutation Status in 
European and Japanese 
Patients with Advanced 
Non-Small-Cell Lung 
Cancer: ASSESS Study 
(Abstract: 35O_PR)
The large international study assessed the use of plasma 
circulating-free tumor derived DNA (ctDNA) versus 
tumor tissues in detecting epidermal growth factor 
receptor (EGFR) mutation status in 1162 matched tissue 
and blood samples from patients with stage IIIA/B/IV 
NSCLC without prior treatment across 56 centers in 
Europe and Japan. Plasma ctDNA testing demonstrated 
an 89% mutation status concordance with the tissue 
testing, in addition to a sensitivity of 46%, specificity 
of 97%, positive predictive value of 93% when tested 
with highly sensitive methods, and a negative predictive 
value of 90%. Overall, the findings suggest that plasma 
ctDNA is a suitable alternative to invasive tissue biopsy 
for EGFR mutation testing, especially for patients 
whose tumor samples are unavailable.
•	 AACR Annual Meeting 
2015: Efficacy of 
Pembrolizumab (MK-
3475) and Relationship 
with PD-L1 Expression in 
Patients with Non-Small 
Cell Lung Cancer: Findings 
from KEYNOTE-001 
(Abstract: CT104)
(ORR; 45.2%) versus PS < 50%. The total population 
of the training and validation cohorts (n=356 evaluable 
patients) achieved longer progression-free survival 
(PFS) and overall survival (OS) in patients with PS ≥ 
50% (mPFS: 6.3 months, mOS: not reached) versus 
PS = 1–49% (mPFS: 3.3 months, mOS: 8.8 months) 
and PS < 1% (mPFS: 2.3 months, mOS: 8.8 months). 
Median duration of response was comparable across the 
groups: PS ≥ 50% (12.4 months), PS = 1–49% (10.3 
months), and PS < 1% (not reached). Drug-related 
adverse events (AEs) included 9% of grade 3–5, 4% 
of discontinuation, and 1 death from pneumonitis. 
Overall, pembrolizumab exerted durable antitumor 
activity and safety in NSCLC patients with or without 
prior treatment. The data also validated ≥ 50% of tumor 
cell membranous PD-L1 expression could potentially 
stratify advanced NSCLC patient for clinical benefit 
from the treatment.
Garon et al. reported findings from the analysis of pembrolizumab 
and the association of its efficacy with PD-L1 expression in an 
independent validation cohort of advanced non-small cell lung 
cancer (NSCLC) with and without prior treatment. The results 
of the trial were also published in the New England Journal of 
Medicine on the same day. In support of the preliminary training 
cohort data, the validation cohort (n=204 evaluable patients) 
with membranous PD-L1 expression in ≥ 50% of tumor cells 
(proportion score [PS] ≥ 50%) had higher overall response rate 
•	 AACR Annual Meeting 
2015: Clinical Safety and 
Efficacy of Pembrolizumab 
(MK-3475) in Patients 
with Malignant Pleural 
Mesothelioma: 
Preliminary Results from 
KEYNOTE-028 (Abstract: 
CT103)
overall response rate (confirmed and unconfirmed) was 
24% (n=6) while disease control rate was 76% (n=13 
with stable disease, n=4 with progressive disease). 
Sixteen patients are still on treatment (for 8+ to 24+ 
weeks). Drug-related adverse events (AEs) were 
observed in 60% of patients, with only 12% of ≥ grade 
3 toxicities. The most common ones were nausea, 
fatigue, and decreased appetite. Immune-related AEs 
was found in 16% of patients; no treatment-related 
deaths or treatment discontinuation due to drug-related 
AEs was observed. The preliminary findings suggest 
that pembrolizumab has robust antitumor activity, with 
a generally well-tolerated toxicity profile, in advanced 
PD-L1 positive MPM.
This study investigated the safety and efficacy of pembrolizumab 
in patients with PD-L1 positive malignant pleural mesothelioma 
(MPM), previously treated with standard therapy. Of the 84 patients 
with MPM screened, 38 were PD-L1 positive. Twenty-five of these 
patients were treated with 10 mg/kg every 2 weeks. Preliminary 
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•	 Smoking Cessation 
Guidelines
“Clinical Recommendations:
•  Pharmacologic therapy is effective and 
recommended.
•    The two most effective pharmacotherapy agents 
are combination nicotine replacement therapy 
(NRT) and varenicline. Therapies can be 
combined as needed.
•   Combining pharmacologic therapy and counseling 
is the most effective and leads to the best results 
for smoking cessation.
•   High-intensity behavior therapy with multiple 
counseling sessions is most effective, but at 
least a minimum of brief counseling is highly 
recommended.
•   Smoking status should be documented in the 
patient health record. Patient health records 
should be updated at regular intervals to indicate 
changes in smoking status, quit attempts made, 
and interventions utilized.
•Smoking relapse and brief slips are common. 
Providers should discuss this and provide guidance 
and support to encourage continued smoking cessation 
attempts. Smoking slips are not necessarily an 
indication to try an alternative method. It may take more 
than one quit attempt with the same therapy to achieve 
long term cessation.”
http://www.nccn.org/about/news/newsinfo.
aspx?NewsID=498
http://www.racgp.org.au/your-practice/guidelines/
smoking-cessation/
http://www.ahrq.gov/professionals/clinicians-
providers/guidelines-recommendations/tobacco/
clinicians/update/treating_tobacco_use08.pdf
https://www.nice.org.uk/guidance/ph10
On March 13, 2015 the NCCN Clinical Practice Guidelines in 
Oncology for Smoking Cessation were presented at the NCCN 20th 
Annual Conference. The chair of the guidelines panel, Dr. Peter G. 
Shields recommends for all cancer patients that smoke “evidence-
based pharmacotherapy, behavior therapy, and close follow-up 
with retreatment.” These guidelines join other published guidelines 
from the English-speaking world including those from the Royal 
Australian College of General Practitioners, the CDC and Agency for 
Healthcare Research and Quality and NICE guidelines from the UK. 
The guidelines all cover similar ground and are readily accessible 
online for practising clinicians. The NCCN guidelines carry a useful 
summary as follows, food for thought in a busy clinic:
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The Lancet and Lancet Oncology have launched a joint campaign 
towards cancer control which focuses on recommendations for 
cancer in various parts of the world, endorses a global cancer fund 
and provides a “roadmap [for] a tobacco-free world by 2040.” The 
launch, in March 2015, coincided with the 16th World Conference 
for Tobacco or Health, in Abu Dhabi, UAE. The Lancet editorial 
addressing the tobacco control component of the campaign refers 
to three papers in particular. The first, which looks at the steps 
required to achieve a tobacco-free world, identifies among other 
things, the need for a “turbo-charged” extras on top of FCTC 
implementation (a slow and patient process if there ever was one) 
with “UN leadership, full engagement of all sectors, and increased 
investment in tobacco control.” The second paper, close to this 
column’s heart, is called “The Road to Effective Tobacco Control 
in China”, displays the increase in cigarette production in China 
over the last 60 years and as key messages, puts forward data on 
•	 Tobacco Control in the 
Lancet Cancer Control 
Campaign
the extremely high prevalence of tobacco use in men, 
high SHS exposure, increasing awareness of the health 
impact of tobacco and the importance of interference 
by the tobacco industry in obstructing tobacco control 
measures. The third paper, which looks at the tobacco 
industry in low and middle-income countries, identifies 
and explores the keys to the survival of the tobacco 
industry: poorer countries, the current low rate of 
smoking in women in those countries (which makes 
them ready for exploitation) and introduction in those 
countries of smoking to the young, all of which need 
pre-emptive action from the forces of tobacco control.
http://www.thelancet.com/campaigns/
cancer?utm_source=email&utm_medium=EM2&utm_
campaign=cancer
http://www.thelancet.com/journals/lancet/article/
PIIS0140-6736%2815%2960133-7/fulltext
http://www.thelancet.com/pdfs/journals/lancet/
PIIS0140-6736%2815%2960174-X.pdf
http://www.thelancet.com/pdfs/journals/lancet/
PIIS0140-6736%2815%2960312-9.pdf
Some of the subtleties of the e-cigarette debate are brought out by an 
article in the Daily Mail (not itself known for subtlety) reporting on 
research that suggests a difference in impact on smoking cessation 
by different types of e-cigarettes. There are “cigalike” e-cigarettes 
(that look like tobacco cigarettes and have disposable cartridges) and 
“tank” e-cigarettes (that have a refillable liquid component). Research 
published in Nicotine Tobacco Research and Addiction on the results 
•	 E-Cigarette Update of online surveys of adult smokers in Great Britain 
indicate a greater likelihood of smoking cessation amongst 
users of the “tank” variety of e-cigarettes compared 
with non-daily users of e-cigarettes. Users of “cigalike” 
e-cigarettes did no better or did worse than non-daily 
users. The authors of the first Lancet paper above, “A 
tobacco-free world: a call to action to phase out the sale of 
tobacco products by 2040” refers to e-cigarettes as “both 
a challenge and an opportunity”, describing best case 
(e-cigarettes aid cessation and replace tobacco without 
uptake by non-smokers) and worst case (e-cigarettes are 
ineffective for smoking cessation and vaping accelerates 
in prior non-smokers) scenarios. The e-cigarette debate, 
like tobacco control itself, is complex and demanding and 
needs attention to detail.
http://www.dailymail.co.uk/health/article-3047441/
Smokers-quit-smoking-e-cigarette-day-likely-succeed.html
Nicotine Tob Res. 2015 Apr 20. pii: ntv078.
Addiction. 2015 Apr 21. doi: 10.1111/add.12917.
Image source: NCI
